Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

162 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.
Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, Scaltriti M, Bromberg JF, Ladanyi M, Hyman DM, Drilon A, Zehir A, Benayed R, Chandarlapaty S, Hechtman JF. Ross DS, et al. Among authors: drilon a. Ann Oncol. 2020 Aug;31(8):991-1000. doi: 10.1016/j.annonc.2020.04.008. Epub 2020 Apr 26. Ann Oncol. 2020. PMID: 32348852 Free PMC article.
TRK inhibitors in TRK fusion-positive cancers.
Drilon A. Drilon A. Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30. doi: 10.1093/annonc/mdz282. Ann Oncol. 2019. PMID: 31738426 Free PMC article. Review.
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR, Rosen E, Guo R, Basu E, Li BT, Harding JJ, Iyer G, Jhaveri K, Gounder MM, Shukla NN, Roberts SS, Glade-Bender J, Kaplanis L, Schram A, Hyman DM, Drilon A. Liu D, et al. Among authors: drilon a. Ann Oncol. 2020 Sep;31(9):1207-1215. doi: 10.1016/j.annonc.2020.05.006. Epub 2020 May 15. Ann Oncol. 2020. PMID: 32422171 Free PMC article.
COVID-19 in patients with lung cancer.
Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, McCarthy CG, Falcon CJ, Schoenfeld AJ, Arbour KC, Chaft JE, Daly RM, Drilon A, Eng J, Iqbal A, Lai WV, Li BT, Lito P, Namakydoust A, Ng K, Offin M, Paik PK, Riely GJ, Rudin CM, Yu HA, Zauderer MG, Donoghue MTA, Łuksza M, Greenbaum BD, Kris MG, Hellmann MD. Luo J, et al. Among authors: drilon a. Ann Oncol. 2020 Oct;31(10):1386-1396. doi: 10.1016/j.annonc.2020.06.007. Epub 2020 Jun 17. Ann Oncol. 2020. PMID: 32561401 Free PMC article.
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors.
Rosen EY, Schram AM, Young RJ, Schreyer MW, Hechtman JF, Shu CA, Ku NC, Hyman DM, Drilon A. Rosen EY, et al. Among authors: drilon a. JCO Precis Oncol. 2019 May 16;3:PO.19.00009. doi: 10.1200/PO.19.00009. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914009 Free PMC article. No abstract available.
Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology.
Tao JJ, Eubank MH, Schram AM, Cangemi N, Pamer E, Rosen EY, Schultz N, Chakravarty D, Philip J, Hechtman JF, Harding JJ, Smyth LM, Jhaveri KL, Drilon A, Ladanyi M, Solit DB, Zehir A, Berger MF, Stetson PD, Gardos SM, Hyman DM. Tao JJ, et al. Among authors: drilon a. JCO Precis Oncol. 2019 Jul 24;3:PO.19.00066. doi: 10.1200/PO.19.00066. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914018 Free PMC article.
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.
Italiano A, Nanda S, Briggs A, Garcia-Foncillas J, Lassen U, Vassal G, Kummar S, van Tilburg CM, Hong DS, Laetsch TW, Keating K, Reeves JA, Fellous M, Childs BH, Drilon A, Hyman DM. Italiano A, et al. Among authors: drilon a. Cancers (Basel). 2020 Nov 4;12(11):3246. doi: 10.3390/cancers12113246. Cancers (Basel). 2020. PMID: 33158040 Free PMC article.
162 results